Q3 2025 Management View Ian Mortimer, President and CEO, highlighted three critical priorities: completion of the Phase III X ...

Yet, the expectation from all of this healthcare-generated data is that we in primary care, primarily, will be the ones reviewing all of it, dealing with it, getting back to our patients about it, ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Food and Drug Administration no longer agreed that clinical data for the Dutch company's gene therapy for Huntington's disease may be adequate for a marketing application, triggering a 57% slump in ...

Investors are watching for private updates on the job market as the government shutdown is days away from becoming the ...

UnitedHealth's Q3 earnings surpassed expectations, breaking a missing streak and signaling a potential operational turnaround ...

UTime (WTO) outlined its ongoing exploration in the field of health data analysis, particularly the potential application of artificial ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

The future of medicine won't be defined by the smartest AI in the room, but by the most integrated and accessible ecosystem ...

CVS Health rode double-digit sales growth from drugstores and its pharmacy benefits management business to a ...

Texas Attorney General Ken Paxton announced Tuesday he had filed a lawsuit against Tylenol's manufacturer, citing numerous ...

While research has long held the far right to be the most persistent domestic terror threat, a controversial new report ...